Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 09:30PM GMT
Release Date Price: €69 (+1.47%)
Cory William Kasimov
JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good afternoon, everyone. My name is Cory Kasimov. I'm the senior biotech analyst at JPMorgan. It's my pleasure to introduce the next company. I'm glad Jamie stopped talking to give him his full allotment, but we have Sage Therapeutics and the company's CEO, Jeff Jonas, with us. Please note that following Jeff's presentation, there will be a breakout across the hall in the Georgian room.

With that, I turn it over to Jeff.

Jeffrey M. Jonas
Sage Therapeutics, Inc. - CEO, President & Director

Good afternoon, everyone. Thanks for coming. Just before this started, I was given the opportunity to cut off Jamie. I wisely declined. The -- so this is our safe harbor. And again, we're going to be making some forward-looking statements today. Refer to our filings for further details.

I'm going to begin today with a little bit of an overview of what's made Sage -- what's driven the folks at Sage. What we think -- what our vision really is and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot